-
-
- R&D Unit
- Industrial Vaccine Production Unit
- Vaccine and Immunization Training Unit
- Vaccine Epidemiology Unit
- Preclinical and Clinical Research and Project Coordination Unit
- Epidemiology of Pandemic-Risk Infectious Agents Unit
- Bioterrorism Unit
- Laboratory Animal Production/Testing and Preclinical Research Unit
- Tissue Culture Collection, Viral and Bacterial Culture Banking Unit
- Quality Control Laboratory Unit
- Training, Administrative, and Financial Services Unit
-
-
-
- Announcements
- Key Dates
- FAQ
- Contact
About TAE
Turkish Vaccine Institute was established under the roof of Presidency of Health Institutes of Turkey. It is responsible for developing strategies, constituting infrastructure, support and co-ordinate activities; regarding all kinds of research and development, industrial production and test activities of vaccines, particularly towards contagious diseases to meet the needs of our country.
In the light of scientific, technological and sociological advances, Turkish Vaccine Institute will operate to determine and update prior fields, develop and support new projects considering vaccine technologies and commercialize the ones whose research and development activities are completed.
In addition, the institute aims to co-ordinate activities on building up research teams constituted of multi-disciplined specialists and raising up personal to fulfill the needs of government and private sector so as to realize vaccine production in our country and eliminate dependency to foreign sources.
The institute purposes the continuation of research and development activities so as to answer a possible epidemic spread in the future and enhance vaccine strategies towards diseases with no current treatments. In this connection, it has become the highest priority of the institute to develop and produce vaccines with local sources, and co-ordinate the whole process for the sake of the healthcare in our country since the Covid-19 pandemic. It plays an active role in conducting clinical trials of the Covid-19 vaccines, production of doses required and their mass production after certification of their application.
The institute will continue to play an active role in the development of novel vaccines towards other agents as it did by supporting and coordinating the native vaccine produced for SARS-CoV-2 agent. In particular, it has been targeted to develop vaccines against Hepatitis A, Hepatitis B, Bacille Calmette Guerin (BCG), Quintet Combination Vaccine (Diphtheria- Pertussis-Tetanus-Hib-Poliomyelitis), Triple Combination Vaccine (Rubeola-Rubella-Epidemic Parotitis), Conjugated Pneumococcus (PCV13), Polio, Varicella Zoster and Haemophilus Influenza Type-B, and against pathogens such as Rabies and Influenza.